RÉSUMÉ
Concomitant with DNA replication, the chromosomal cohesin complex establishes cohesion between newly replicated sister chromatids. Cohesion establishment requires acetylation of conserved cohesin lysine residues by Eco1 acetyltransferase. Here, we explore how cohesin acetylation is linked to DNA replication. Biochemical reconstitution of replication-coupled cohesin acetylation reveals that transient DNA structures, which form during DNA replication, control the acetylation reaction. As polymerases complete lagging strand replication, strand displacement synthesis produces DNA flaps that are trimmed to result in nicked double-stranded DNA. Both flaps and nicks stimulate cohesin acetylation, while subsequent nick ligation to complete Okazaki fragment maturation terminates the acetylation reaction. A flapped or nicked DNA substrate constitutes a transient molecular clue that directs cohesin acetylation to a window behind the replication fork, next to where cohesin likely entraps both sister chromatids. Our results provide an explanation for how DNA replication is linked to sister chromatid cohesion establishment.
Sujet(s)
Chromatides , Protéines de Saccharomyces cerevisiae , Chromatides/métabolisme , Protéines nucléaires/métabolisme , Saccharomyces cerevisiae/génétique , Saccharomyces cerevisiae/métabolisme , Protéines de Saccharomyces cerevisiae/génétique , Protéines de Saccharomyces cerevisiae/métabolisme , Réplication de l'ADN , Protéines du cycle cellulaire/génétique , Protéines du cycle cellulaire/métabolisme , ADN , Acetyltransferases/génétique , Acetyltransferases/métabolismeRÉSUMÉ
The DNA damage response (DDR) checkpoint is activated when DNA is damaged or when DNA replication forks stall. The DDR checkpoint plays a critical role in preserving the integrity of stalled replication forks; this is essential for subsequent fork resumption, faithful and complete genome replication, and cell survival. The mechanisms by which the DDR checkpoint preserves stalled replication forks are still incompletely understood. Many substrates of the DDR checkpoint kinases have been identified over the years, but in many cases the functional consequences of phosphorylation are still unclear. Emerging as a complementary approach, recent advances in biochemical reconstitution of DNA replication have made it possible to characterise specific mechanisms of DNA replication regulation by the DDR checkpoint. In this review, we discuss the role of DNA replication in the activation of the DDR checkpoint and how this checkpoint regulates different aspects of DNA replication. We then distinguish between checkpoint action locally at the site of replication stalling and more globally, and we discuss how these functions contribute to coordinating complete replication of the genome in the face of replication stress.
Sujet(s)
Réplication de l'ADN , Saccharomycetales , Points de contrôle du cycle cellulaire , ADN , Altération de l'ADN , Saccharomycetales/génétiqueRÉSUMÉ
The coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health challenge. While the efficacy of vaccines against emerging and future virus variants remains unclear, there is a need for therapeutics. Repurposing existing drugs represents a promising and potentially rapid opportunity to find novel antivirals against SARS-CoV-2. The virus encodes at least nine enzymatic activities that are potential drug targets. Here, we have expressed, purified and developed enzymatic assays for SARS-CoV-2 nsp13 helicase, a viral replication protein that is essential for the coronavirus life cycle. We screened a custom chemical library of over 5000 previously characterized pharmaceuticals for nsp13 inhibitors using a fluorescence resonance energy transfer-based high-throughput screening approach. From this, we have identified FPA-124 and several suramin-related compounds as novel inhibitors of nsp13 helicase activity in vitro. We describe the efficacy of these drugs using assays we developed to monitor SARS-CoV-2 growth in Vero E6 cells.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , Évaluation préclinique de médicament , RNA helicases/antagonistes et inhibiteurs , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Animaux , Chlorocebus aethiops , Dosages enzymatiques , Transfert d'énergie par résonance de fluorescence , Tests de criblage à haut débit , RNA helicases/métabolisme , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/composition chimique , Suramine/pharmacologie , Cellules Vero , Protéines virales non structurales/métabolismeRÉSUMÉ
The coronavirus disease 2019 (COVID-19) global pandemic has turned into the largest public health and economic crisis in recent history impacting virtually all sectors of society. There is a need for effective therapeutics to battle the ongoing pandemic. Repurposing existing drugs with known pharmacological safety profiles is a fast and cost-effective approach to identify novel treatments. The COVID-19 etiologic agent is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded positive-sense RNA virus. Coronaviruses rely on the enzymatic activity of the replication-transcription complex (RTC) to multiply inside host cells. The RTC core catalytic component is the RNA-dependent RNA polymerase (RdRp) holoenzyme. The RdRp is one of the key druggable targets for CoVs due to its essential role in viral replication, high degree of sequence and structural conservation and the lack of homologues in human cells. Here, we have expressed, purified and biochemically characterised active SARS-CoV-2 RdRp complexes. We developed a novel fluorescence resonance energy transfer-based strand displacement assay for monitoring SARS-CoV-2 RdRp activity suitable for a high-throughput format. As part of a larger research project to identify inhibitors for all the enzymatic activities encoded by SARS-CoV-2, we used this assay to screen a custom chemical library of over 5000 approved and investigational compounds for novel SARS-CoV-2 RdRp inhibitors. We identified three novel compounds (GSK-650394, C646 and BH3I-1) and confirmed suramin and suramin-like compounds as in vitro SARS-CoV-2 RdRp activity inhibitors. We also characterised the antiviral efficacy of these drugs in cell-based assays that we developed to monitor SARS-CoV-2 growth.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , ARN polymérase ARN-dépendante de coronavirus/antagonistes et inhibiteurs , Évaluation préclinique de médicament , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Animaux , Benzoates/pharmacologie , Composés hétérocycliques bicycliques/pharmacologie , Chlorocebus aethiops , ARN polymérase ARN-dépendante de coronavirus/métabolisme , Dosages enzymatiques , Transfert d'énergie par résonance de fluorescence , Tests de criblage à haut débit , Holoenzymes/métabolisme , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/composition chimique , Suramine/pharmacologie , Cellules Vero , Protéines virales non structurales/antagonistes et inhibiteurs , Protéines virales non structurales/métabolismeRÉSUMÉ
SARS-CoV-2 is responsible for COVID-19, a human disease that has caused over 2 million deaths, stretched health systems to near-breaking point and endangered economies of countries and families around the world. Antiviral treatments to combat COVID-19 are currently lacking. Remdesivir, the only antiviral drug approved for the treatment of COVID-19, can affect disease severity, but better treatments are needed. SARS-CoV-2 encodes 16 non-structural proteins (nsp) that possess different enzymatic activities with important roles in viral genome replication, transcription and host immune evasion. One key aspect of host immune evasion is performed by the uridine-directed endoribonuclease activity of nsp15. Here we describe the expression and purification of nsp15 recombinant protein. We have developed biochemical assays to follow its activity, and we have found evidence for allosteric behaviour. We screened a custom chemical library of over 5000 compounds to identify nsp15 endoribonuclease inhibitors, and we identified and validated NSC95397 as an inhibitor of nsp15 endoribonuclease in vitro. Although NSC95397 did not inhibit SARS-CoV-2 growth in VERO E6 cells, further studies will be required to determine the effect of nsp15 inhibition on host immune evasion.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , Évaluation préclinique de médicament , Endoribonucleases/antagonistes et inhibiteurs , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Régulation allostérique , Animaux , Chlorocebus aethiops , Endoribonucleases/isolement et purification , Endoribonucleases/métabolisme , Dosages enzymatiques , Fluorescence , Tests de criblage à haut débit , Techniques in vitro , Cinétique , Naphtoquinones/pharmacologie , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , SARS-CoV-2/croissance et développement , Bibliothèques de petites molécules/composition chimique , Solutions , Cellules Vero , Protéines virales non structurales/isolement et purification , Protéines virales non structurales/métabolismeRÉSUMÉ
The COVID-19 pandemic has emerged as the biggest life-threatening disease of this century. Whilst vaccination should provide a long-term solution, this is pitted against the constant threat of mutations in the virus rendering the current vaccines less effective. Consequently, small molecule antiviral agents would be extremely useful to complement the vaccination program. The causative agent of COVID-19 is a novel coronavirus, SARS-CoV-2, which encodes at least nine enzymatic activities that all have drug targeting potential. The papain-like protease (PLpro) contained in the nsp3 protein generates viral non-structural proteins from a polyprotein precursor, and cleaves ubiquitin and ISG protein conjugates. Here we describe the expression and purification of PLpro. We developed a protease assay that was used to screen a custom compound library from which we identified dihydrotanshinone I and Ro 08-2750 as compounds that inhibit PLpro in protease and isopeptidase assays and also inhibit viral replication in cell culture-based assays.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , Protéases de type papaïne des coronavirus/antagonistes et inhibiteurs , Évaluation préclinique de médicament , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , AMP/analogues et dérivés , AMP/pharmacologie , Alanine/analogues et dérivés , Alanine/pharmacologie , Dérivés de l'aniline/pharmacologie , Animaux , Benzamides/pharmacologie , Chlorocebus aethiops , Protéases de type papaïne des coronavirus/génétique , Protéases de type papaïne des coronavirus/isolement et purification , Protéases de type papaïne des coronavirus/métabolisme , Synergie des médicaments , Dosages enzymatiques , Flavines/pharmacologie , Transfert d'énergie par résonance de fluorescence , Furanes/pharmacologie , Tests de criblage à haut débit , Concentration inhibitrice 50 , Naphtalènes/pharmacologie , Phénanthrènes/pharmacologie , Quinones/pharmacologie , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , SARS-CoV-2/croissance et développement , Bibliothèques de petites molécules/composition chimique , Cellules Vero , Réplication virale/effets des médicaments et des substances chimiquesRÉSUMÉ
SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world causing a deadly pandemic with tremendous social and economic costs. Healthcare systems worldwide are under great pressure, and there is an urgent need for effective antiviral treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic activities of the non-structural proteins (nsp), which makes them interesting targets for the development of new antiviral treatments. With the aim to identify novel SARS-CoV-2 antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor (nsp10) and developed biochemical assays compatible with high-throughput approaches to screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14 exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for further coronavirus research as well as potentially contributing to new therapeutic opportunities for COVID-19.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , Évaluation préclinique de médicament , Exoribonucleases/antagonistes et inhibiteurs , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Protéines virales régulatrices ou accessoires/antagonistes et inhibiteurs , Animaux , Acide aurintricarboxylique/pharmacologie , Chlorocebus aethiops , Dosages enzymatiques , Exoribonucleases/métabolisme , Fluorescence , Tests de criblage à haut débit , Patuline/pharmacologie , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/composition chimique , Cellules Vero , Protéines virales non structurales/métabolisme , Protéines virales régulatrices ou accessoires/métabolismeRÉSUMÉ
The coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activity in vitro, with IC50 values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC50. Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement.
Sujet(s)
Antiviraux/composition chimique , Antiviraux/pharmacologie , Protéases 3C des coronavirus/antagonistes et inhibiteurs , Évaluation préclinique de médicament , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Chlorométhyl cétones d'acides aminés/pharmacologie , Animaux , Azoles/pharmacologie , Chlorocebus aethiops , Protéases 3C des coronavirus/génétique , Protéases 3C des coronavirus/isolement et purification , Protéases 3C des coronavirus/métabolisme , Dosages enzymatiques , Transfert d'énergie par résonance de fluorescence , Tests de criblage à haut débit , Isoindoles , Leupeptines/pharmacologie , Composés organiques du sélénium/pharmacologie , Peptidomimétiques , Protéines de liaison à l'ARN/métabolisme , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/composition chimique , Cellules Vero , Protéines virales non structurales/métabolismeRÉSUMÉ
The COVID-19 pandemic has presented itself as one of the most critical public health challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae family to cause a fatal disease in humans. There is currently only one antiviral compound, remdesivir, that can be used for the treatment of COVID-19. To identify additional potential therapeutics, we investigated the enzymatic proteins encoded in the SARS-CoV-2 genome. In this study, we focussed on the viral RNA cap methyltransferases, which play key roles in enabling viral protein translation and facilitating viral escape from the immune system. We expressed and purified both the guanine-N7 methyltransferase nsp14, and the nsp16 2'-O-methyltransferase with its activating cofactor, nsp10. We performed an in vitro high-throughput screen for inhibitors of nsp14 using a custom compound library of over 5000 pharmaceutical compounds that have previously been characterised in either clinical or basic research. We identified four compounds as potential inhibitors of nsp14, all of which also showed antiviral capacity in a cell-based model of SARS-CoV-2 infection. Three of the four compounds also exhibited synergistic effects on viral replication with remdesivir.
Sujet(s)
Antiviraux/pharmacologie , Évaluation préclinique de médicament , Exoribonucleases/antagonistes et inhibiteurs , Methyltransferases/antagonistes et inhibiteurs , Coiffes des ARN/métabolisme , SARS-CoV-2/enzymologie , Bibliothèques de petites molécules/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , AMP/analogues et dérivés , AMP/pharmacologie , Alanine/analogues et dérivés , Alanine/pharmacologie , Animaux , Antiviraux/composition chimique , Chlorobenzènes/pharmacologie , Chlorocebus aethiops , Dosages enzymatiques , Exoribonucleases/génétique , Exoribonucleases/isolement et purification , Exoribonucleases/métabolisme , Transfert d'énergie par résonance de fluorescence , Tests de criblage à haut débit , Indazoles/pharmacologie , Indènes/pharmacologie , Indoles/pharmacologie , Methyltransferases/génétique , Methyltransferases/isolement et purification , Methyltransferases/métabolisme , Nitriles/pharmacologie , Phénothiazines/pharmacologie , Purines/pharmacologie , Reproductibilité des résultats , SARS-CoV-2/effets des médicaments et des substances chimiques , Bibliothèques de petites molécules/composition chimique , Spécificité du substrat , Triflupéridol/pharmacologie , Cellules Vero , Protéines virales non structurales/génétique , Protéines virales non structurales/isolement et purification , Protéines virales non structurales/métabolisme , Protéines virales régulatrices ou accessoires/génétique , Protéines virales régulatrices ou accessoires/isolement et purification , Protéines virales régulatrices ou accessoires/métabolismeRÉSUMÉ
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries. Although most patients are diagnosed at early stages, 15-20% will relapse despite local treatment. Presently, there are no reliable markers to identify patients with worse outcomes who may benefit from adjuvant treatments, such as chemotherapy, and liquid biopsies may be of use in this setting. Peritoneal lavages are systematically performed during endometrial surgery but little data are available about their potential as liquid biopsies. We analyzed KRAS and PIK3CA mutations in paired surgical biopsies, blood and cytology-negative peritoneal lavages in a cohort of 50 EC patients. Surgical biopsies were submitted to next-generation sequencing (NGS) while circulating-free DNA (cfDNA) purified from plasma and peritoneal lavages was analyzed for KRAS and PIK3CA hotspot mutations using a sensitive quantitative polymerase chain reaction (PCR) assay. NGS of biopsies revealed KRAS, PIK3CA or concomitant KRAS + PIK3CA mutations in 33/50 (66%) EC patients. Of those, 19 cases carried hotspot mutations. Quantitative PCR revealed KRAS and/or PIK3CA mutations in the lavages of 9/19 (47.4%) hotspot EC patients. In contrast, only 2/19 (10.5%) blood samples from hotspot EC patients were positive. Mutations found in cfDNA consistently matched those in paired biopsies. One of the two patients positive in plasma and lavage died in less than 6 months. In conclusion, mutational analysis in peritoneal lavages and blood from early stage EC is feasible. Further studies are warranted to determine if it might help to identify patients with worse prognosis. Human genes discussed: KRAS, KRAS proto-oncogene, GTPase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
Sujet(s)
Tumeurs de l'endomètre/génétique , Mutation , Sujet âgé , Sujet âgé de 80 ans ou plus , Allèles , Phosphatidylinositol 3-kinases de classe I/génétique , Analyse de mutations d'ADN , ADN circulaire/sang , ADN circulaire/génétique , Tumeurs de l'endomètre/sang , Tumeurs de l'endomètre/anatomopathologie , Femelle , Séquençage nucléotidique à haut débit , Humains , Biopsie liquide , Adulte d'âge moyen , Lavage péritonéal/méthodes , Étude de validation de principe , Proto-oncogène Mas , Protéines proto-oncogènes p21(ras)/génétique , Réaction de polymérisation en chaine en temps réelRÉSUMÉ
Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis.
Sujet(s)
Marqueurs biologiques tumoraux/génétique , Vésicules extracellulaires/génétique , Tumeurs du poumon/génétique , microARN/métabolisme , Plèvre/métabolisme , Irrigation thérapeutique , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Gene Ontology , Humains , Tumeurs du poumon/diagnostic , Mâle , Adulte d'âge moyen , ARN messager/génétique , ARN messager/métabolismeRÉSUMÉ
BACKGROUND: Colorectal cancer (CRC) is the third leading cause of cancer-related mortality worldwide. Current systematic methods for diagnosing have inherent limitations so development of a minimally-invasive diagnosis, based on the identification of sensitive biomarkers in liquid biopsies could therefore facilitate screening among population at risk. METHODS: In this study, we aim to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the peritoneal lavage as a source of potential miRNA diagnostic biomarkers. We isolated EVs by ultracentrifugation from 25 ascitic fluids and 25 peritoneal lavages from non-cancer and CRC patients, respectively. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 371 miRNAs. RESULTS: 210 miRNAs were significantly dysregulated (adjusted p value < 0.05 and abs(logFC) ≥ 1). The top-10 miRNAs, which had the AUC value higher than 0.95, were miRNA-199b-5p, miRNA-150-5p, miRNA-29c-5p, miRNA-218-5p, miRNA-99a-3p, miRNA-383-5p, miRNA-199a-3p, miRNA-193a-5p, miRNA-10b-5p and miRNA-181c-5p. CONCLUSIONS: This finding opens the avenue to the use of EV-associated miRNA of peritoneal lavages as an untapped source of biomarkers for CRC.
Sujet(s)
Adénocarcinome/diagnostic , Liquide d'ascite/métabolisme , Marqueurs biologiques tumoraux , Tumeurs colorectales/diagnostic , Vésicules extracellulaires/génétique , microARN/génétique , Adénocarcinome/génétique , Adénocarcinome/métabolisme , Adénocarcinome/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Liquide d'ascite/anatomopathologie , Marqueurs biologiques tumoraux/génétique , Marqueurs biologiques tumoraux/métabolisme , Études cas-témoins , Études de cohortes , Tumeurs colorectales/génétique , Tumeurs colorectales/métabolisme , Tumeurs colorectales/anatomopathologie , Vésicules extracellulaires/métabolisme , Femelle , Analyse de profil d'expression de gènes/méthodes , Régulation de l'expression des gènes tumoraux , Humains , Mâle , microARN/métabolisme , Adulte d'âge moyen , Séquençage par oligonucléotides en batterie , Lavage péritonéal , PronosticRÉSUMÉ
Endometrial cancer (EC) is the sixth most common cancer in women worldwide and is responsible for more than 89,000 deaths every year. Mortality is associated with presence of poor prognostic factors at diagnosis, i.e., diagnosis at an advanced stage, with a high grade and/or an aggressive histology. Development of novel approaches that would permit us to improve the clinical management of EC patients is an unmet need. In this study, we investigate a novel approach to identify highly sensitive and specific biomarkers of EC using extracellular vesicles (EVs) isolated from the peritoneal lavage of EC patients. EVs of peritoneal lavages of 25 EC patients were isolated and their miRNA content was compared with miRNAs of EVs isolated from the ascitic fluid of 25 control patients. Expression of the EV-associated miRNAs was measured using the Taqman OpenArray technology that allowed us to detect 371 miRNAs. The analysis showed that 114 miRNAs were significantly dysregulated in EC patients, among which eight miRNAs, miRNA-383-5p, miRNA-10b-5p, miRNA-34c-3p, miRNA-449b-5p, miRNA-34c-5p, miRNA-200b-3p, miRNA-2110, and miRNA-34b-3p, demonstrated a classification performance at area under the receiver operating characteristic curve (AUC) values above 0.9. This finding opens an avenue for the use of EV-associated miRNAs of peritoneal lavages as an untapped source of biomarkers for EC.
RÉSUMÉ
The two most frequent types of endometrial cancer (EC) are endometrioid (EEC) and serous carcinomas (SC). Differential diagnosis between them is not always easy. A subset of endometrial cancers shows misleading microscopical features, which cause problems in differential diagnosis, and may be a good scenario for next-generation sequencing. Previous studies have assessed the usefulness of targeted sequencing with panels of generic cancer-associated genes in EC histological typing. Based on the analysis of TCGA (The Cancer Genome Atlas), EEC and SC have different mutational profiles. In this proof of principle study, we have performed targeted sequencing analysis with a customized panel, based on the TCGA mutational profile of EEC and SC, in a series of 24 tumors (16 EEC and 8 SC). Our panel comprised coding and non-coding sequences of the following genes: ABCC9, ARID1A, ARID5B, ATR, BCOR, CCND1, CDH19, CHD4, COL11A1, CSDE1, CSMD3, CTCF, CTNNB1, EP300, ERBB2, FBXW7, FGFR2, FOXA2, KLLN, KMT2B, KRAS, MAP3K4, MKI67, NRAS, PGAP3, PIK3CA, PIK3R1, PPP2R1A, PRPF18, PTEN, RPL22, SCARNA11, SIN3A, SMARCA4, SPOP, TAF1, TP53, TSPYL2, USP36, and WRAP53. Targeted sequencing validation by Sanger sequencing and immunohistochemistry was performed in a group of genes. POLE mutation status was assessed by Sanger sequencing. The most mutated genes were PTEN (93.7%), ARID1A (68.7%), PIK3CA (50%), and KMT2B (43.7%) for EEC, and TP53 (87.5%), PIK3CA (50%), and PPP2R1A (25%) for SC. Our panel allowed correct classification of all tumors in the two categories (EEC, SC). Coexistence of mutations in PTEN, ARID1A, and KMT2B was diagnostic of EEC. On the other hand, absence of PTEN, ARID1A, and KMT2B mutations in the presence of TP53 mutation was diagnostic of SC. This proof of concept study demonstrates the suitability of targeted sequencing with a customized endometrial cancer gene panel as an additional tool for confirming histological typing.
Sujet(s)
Carcinome endométrioïde/anatomopathologie , Cystadénocarcinome séreux/anatomopathologie , Tumeurs de l'endomètre/anatomopathologie , Protéines nucléaires/génétique , Facteurs de transcription/génétique , Adénocarcinome à cellules claires/génétique , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques tumoraux/génétique , Protéines de liaison à l'ADN/génétique , Femelle , Humains , Immunohistochimie/méthodes , Mâle , Adulte d'âge moyen , Mutation/génétique , Protéines de liaison à l'ARN/génétiqueRÉSUMÉ
Transcription and replication complexes can coincide in space and time. Such coincidences may result in collisions that trigger genomic instability. The phosphorylation of Mrc1 by different signaling kinases is part of a general mechanism that serves to delay replication in response to different stresses that trigger a massive transcriptional response in S phase. This mechanism prevents Transcription-Replication Conflicts and maintains genomic integrity in response to unscheduled massive transcription during S phase.
RÉSUMÉ
Conflicts between replication and transcription machineries represent a major source of genomic instability and cells have evolved strategies to prevent such conflicts. However, little is known regarding how cells cope with sudden increases of transcription while replicating. Here, we report the existence of a general mechanism for the protection of genomic integrity upon transcriptional outbursts in S phase that is mediated by Mrc1. The N-terminal phosphorylation of Mrc1 blocked replication and prevented transcription-associated recombination (TAR) and genomic instability during stress-induced gene expression in S phase. An unbiased kinome screening identified several kinases that phosphorylate Mrc1 at the N terminus upon different environmental stresses. Mrc1 function was not restricted to environmental cues but was also required when unscheduled transcription was triggered by low fitness states such as genomic instability or slow growth. Our data indicate that Mrc1 integrates multiple signals, thereby defining a general safeguard mechanism to protect genomic integrity upon transcriptional outbursts.
Sujet(s)
Protéines du cycle cellulaire/génétique , Réplication de l'ADN , Régulation de l'expression des gènes fongiques , Instabilité du génome , Protein-Serine-Threonine Kinases/génétique , Protéines de Saccharomyces cerevisiae/génétique , Saccharomyces cerevisiae/génétique , Transcription génétique , Protéines du cycle cellulaire/métabolisme , Escherichia coli/génétique , Escherichia coli/métabolisme , Glucose/déficit , Température élevée , Peroxyde d'hydrogène/pharmacologie , Pression osmotique , Stress oxydatif/génétique , Phosphorylation , Protein-Serine-Threonine Kinases/métabolisme , Protéines recombinantes/génétique , Protéines recombinantes/métabolisme , Phase S , Saccharomyces cerevisiae/effets des médicaments et des substances chimiques , Saccharomyces cerevisiae/métabolisme , Protéines de Saccharomyces cerevisiae/métabolisme , Transduction du signal , Chlorure de sodium/pharmacologieRÉSUMÉ
Endometrial carcinoma (EC) shows intertumor heterogeneity, with several different histologic types differing in their morphologic and molecular features. There is also intratumoral morphologic heterogeneity, with different neoplastic cell components within the same tumor, with different morphologic and molecular features. In this article, we discuss the consequences of tumor heterogeneity in EC at the morphologic and molecular levels, by describing some illustrative examples produced by the research team. They are (1) morphologic heterogeneity in conventional EC and mixed tumors, (2) EC with microsatellite instability, (3) branched evolution as shown by exome sequencing analysis, (4) morphologic, molecular, and metabolomic differences between the tumor surface and myometrial invasion front, (5) tumor heterogeneity at the microenviromental level, (6) the sensitivity of endometrial aspirates to detect tumor heterogeneity in EC, and (7) sampling strategies to detect tumor heterogeneity in hysterectomy specimens. Tumor heterogeneity may have an important clinical impact, since it can be challenging to identify minor tumor cell populations that may have an impact on diagnosis, prognosis, and therapeutic decisions for patients with EC.
Sujet(s)
Marqueurs biologiques tumoraux/génétique , Tumeurs de l'endomètre/génétique , Hétérogénéité génétique , Tumeurs de l'ovaire/génétique , Marqueurs biologiques tumoraux/métabolisme , Lignage cellulaire , Évolution clonale , Tumeurs de l'endomètre/diagnostic , Tumeurs de l'endomètre/métabolisme , Tumeurs de l'endomètre/anatomopathologie , Exome/génétique , Femelle , Humains , Métabolomique , Instabilité des microsatellites , Mutation , Tumeurs de l'ovaire/diagnostic , Tumeurs de l'ovaire/métabolisme , Tumeurs de l'ovaire/anatomopathologie , Phénotype , Pronostic , Protéomique , Microenvironnement tumoralRÉSUMÉ
Upon environmental changes, proliferating cells delay cell cycle to prevent further damage accumulation. Yeast Cip1 is a Cdk1 and Cln2-associated protein. However, the function and regulation of Cip1 are still poorly understood. Here we report that Cip1 expression is co-regulated by the cell-cycle-mediated factor Mcm1 and the stress-mediated factors Msn2/4. Overexpression of Cip1 arrests cell cycle through inhibition of Cdk1-G1 cyclin complexes at G1 stage and the stress-activated protein kinase-dependent Cip1 T65, T69, and T73 phosphorylation may strengthen the Cip1and Cdk1-G1 cyclin interaction. Cip1 accumulation mainly targets Cdk1-Cln3 complex to prevent Whi5 phosphorylation and inhibit early G1 progression. Under osmotic stress, Cip1 expression triggers transient G1 delay which plays a functionally redundant role with another hyperosmolar activated CKI, Sic1. These findings indicate that Cip1 functions similarly to mammalian p21 as a stress-induced CDK inhibitor to decelerate cell cycle through G1 cyclins to cope with environmental stresses.A G1 cell cycle regulatory kinase Cip1 has been identified in budding yeast but how this is regulated is unclear. Here the authors identify cell cycle (Mcm1) and stress-mediated (Msn 2/4) transcription factors as regulating Cip1, causing stress induced CDK inhibition and delay in cell cycle progression.
Sujet(s)
Cycle cellulaire , Inhibiteur p21 de kinase cycline-dépendante/métabolisme , Cyclines/métabolisme , Régulation de l'expression des gènes fongiques , Protéines de Saccharomyces cerevisiae/métabolisme , Protéines de liaison à l'ADN/métabolisme , Protéine-1 de maintenance des minichromosomes/métabolisme , Mitogen-Activated Protein Kinases/métabolisme , Pression osmotique , Saccharomyces cerevisiae , Stress physiologique , Facteurs de transcription/métabolismeRÉSUMÉ
Endometrial carcinoma is the most common cancer of the female genital tract. This review article discusses the usefulness of molecular techniques to classify endometrial carcinoma. Any proposal for molecular classification of neoplasms should integrate morphological features of the tumors. For that reason, we start with the current histological classification of endometrial carcinoma, by discussing the correlation between genotype and phenotype, and the most significant recent improvements. Then, we comment on some of the possible flaws of this classification, by discussing also the value of molecular pathology in improving them, including interobserver variation in pathologic interpretation of high grade tumors. Third, we discuss the importance of applying TCGA molecular approach to clinical practice. We also comment on the impact of intratumor heterogeneity in classification, and finally, we will discuss briefly, the usefulness of TCGA classification in tailoring immunotherapy in endometrial cancer patients. We suggest combining pathologic classification and the surrogate TCGA molecular classification for high-grade endometrial carcinomas, as an option to improve assessment of prognosis.